Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Paris 10, France Clinical Trials

A listing of Paris 10, France clinical trials actively recruiting patients volunteers.

Found (80) clinical trials

Evaluation of SAR408701 in Patients With Advanced Solid Tumors

The study duration for an individual patient will start from the signature of the informed consent, will include a period to assess eligibility (screening period) of up to approximately 4 weeks (28 days), a treatment period and an end-of-treatment visit around 30 days following the last administration of study drug, …

Phase

3.6 miles

Learn More »

Evaluation of EYS606 in Patients With Non-infectious Posterior Intermediate or Panuveitis

The maximum study duration per patient is 27 Weeks (including an up to 3 week screening period + 24 weeks follow-up after treatment). The study is conducted in 2 parts. Part 1 is a dose escalation phase which will investigate three pEYS606 doses levels (lower, intermediate and higher dose) over …

Phase

3.62 miles

Learn More »

Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors RET Fusion-Positive Solid Tumors and Medullary Thyroid Cancer

This is an open-label, multi-center Phase 1/2 study in patients with advanced solid tumors, including RET fusion-positive solid tumors, MTC, and other tumors with RET activation. The trial will be conducted in 2 parts: phase 1 (dose escalation) and phase 2 (dose expansion). Patients with advanced cancer are eligible if …

Phase

3.97 miles

Learn More »

Treatment of Familiar Lymphohistiocytosis

The hemophagocytic lymphohistiocytosis (HLH) or lymphohistiocytic activation syndrome is an inflammatory condition caused by a uncontrolled proliferation of activated lymphocytes and macrophages secreting an excess of inflammatory cytokines. Familial hemophagocytic lymphohistiocytosis (FHL) is a rare disorder of the immune system, which is invariably fatal when untreated. Treatment requires the achievement …

Phase

3.97 miles

Learn More »

Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor

Fanconi anemia is an autosomal recessive disease with an average survival of around 24 years old. The number of cells producted by bone marrow decreases around 5-10 years old. Hematological symptoms occur around 7 years old. 80% of patients with Fanconi anemia have clinical signs of bone marrow failure in …

Phase

3.97 miles

Learn More »

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201) a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered Non-infectious Virus (AAV) as a "Shuttle".

In this study researchers want to gather more information about safety and effectiveness of BAY 2599023 (DTX201), a drug therapy that delivers the human factor VIII gene into the human body by use of a viral vector to treat the disease. By replacing the defective gene with a healthy copy …

Phase

3.97 miles

Learn More »

Tolerance and Pharmacokinetics With Capecitabine 5 Out of 7 Days Regimen

Standard administration of capecitabine use a 14 days administration. Routine practice in several intitution leads to use a 5 out of 7 days regimen, with less toxicity. Purpose : to compare the pharmacokinetics of capecitabine, administered 5 days out of 7, as compared to the standard administration (14 days out …

Phase

3.97 miles

Learn More »

Topical QR-313 in Dominant Dystrophic Epidermolysis Bullosa (DDEB) or Recessive Dystrophic Epidermolysis Bullosa (RDEB) Due to Mutation(s) in Exon 73 of the COL7A1gene

This clinical trial will evaluate the safety and tolerability, proof of mechanism, systemic exposure and preliminary efficacy following topical application of QR-313 to subjects with confirmed DDEB or RDEB with one or more pathogenic mutations in exon 73 in the COL7A1 gene. Up to two Target Wound Areas (TWAs) per …

Phase

3.97 miles

Learn More »

Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS

General context: As of March 13, 2020, more than 145,000 cases of 2019-nCoV infection have been confirmed with 5,500 deaths worldwide. As of March 21, 14,469 cases have been confirmed in France, of which 562 have been fatal while 1,525 patients are currently hospitalized in intensive care units. Whereas the …

Phase

3.97 miles

Learn More »